Clinical Research Finder

Children's Hospital of Philadelphia leads or participates in hundreds of clinical trials. Use this database to learn the purpose of these trials, find out who can participate and more.

Find a Clinical Research Study

11 - 20 of 147

HR-pQCT Pilot Study

A new, safe, state-of-the-art technique called HR-pQCT (high resolution peripheral quantitative computed tomography) can be used to measure bone health in children and adults. Because children have growing bones, researchers at CHOP need to develop measurement techniques that work best for children as they grow and transition to adulthood. This study will measure bone density and structure of the arm and leg in healthy children and adults to establish the best way to take these measurements. This study is needed so that future studies can use HR-pQCT to diagnose and monitor treatment of poor bone health in children with complex medical problems. IRB 14-011057

PATS (Pediatric Adenotonsillectomy for Snoring)

The purpose of the study is to study the effect of adenotonsillectomy surgery (removal of tonsils and adenoids) in mild disordered breathing. All participants will in the study will be evaluated for surgery because adenotonsillectomy is a commonly used treatment for MSDB; however, one group will get surgery early (within one month after a sleep study) and the other group will be observed without surgery for 12 months.  After 12 months, subjects who did not get surgery may be reevaluated for surgery by the ear, nose and throat doctor to decide whether they should get surgery or not.  Following confirmation of initial eligibility including screening sleep study, participants will undergo the following procedures: urine collection for cotinine, medical history and physical examination including blood pressure and anthropometry, behavioral testing, questionnaire completion by parent, venipuncture, actigraphy.  If subjects have questions or concerns about the study Dr. Ignacio Tapia (PI) Laurie Karamessinis 215-590-9184 research coordinator, and Mary Anne Cornaglia, research coordinator can be reached at 215-590-3749 or 267-426-5748. IRB 14-011214 

Omics Study for CDG Patient

This is an intergrated study of patients with congenital glycosylation disorder, including genetic conditions in the synthesis of glycoconjugates (congenital disorder of glycosyaltion), degradation of glycoconjugates (majority of lysosomal storage conditions), as well as the metabolism of glycoconjugates (such as certain inborn errors of metabolism that involved in nucleitide sugar metabolism, such as galactosemia, fructose intolarance, or certain glycogen storage conditions). Study methods includes glycomics analysis of body fluid or cells or tissues from patients, relevant metabolomics and genomics analysis. IRB 14-011223

RTA-408 in Friedreich Ataxia

The Children’s Hospital of Philadelphia is recruiting patients with Friedreich’s ataxia (FA) in the United States for a Phase 2 clinical trial studying the safety and effects of RTA 408 in FA. This drug has potential antioxidant properties and we are looking to see how it affects the symptoms of FA. In order to participate, you must have genetic confirmation of FA, maintain stable exercise and medications throughout the study, and discontinue all antioxidant supplements. This is a double-blind placebo-control trial, so half of all subjects will receive study drug and half will receive placebo. Each subject's study participation would last 12 months and include 10 study visits to CHOP. IRB 14-011262

Microbiome Study

We are looking for patients with and without Inflammatory Bowel Disease to participate in an 8 week study on the human microbiome. The microbiome encompasses the trillions of microbes--bacteria, viruses, and other living things that our bodies carry. The study will include 3 study visits to collect clinical information, oral swabs, rectal swabs, stool samples, and blood sample (if applicable). IRB 15-011817

SA237 in NMO

This study will evaluate the efficacy and safety of SA237 compared with placebo in subjects with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD). Males and females age 12-17 years diagnosed with NMO or NMOSD will be eligible to participate. Caregivers will also be asked to complete questionnaires about themselves and will be considered subjects. Procedures include biological specimen collection, radiologic screenings, and questionnaires. The PI for this study is Dr. Sarah Hopkins who can be contacted at 215-590-1719 or hopkinss1@email.chop.edu. IRB 15-012095

Progressive Degeneration in Pediatric MS

The purpose of this research study is to learn more about childhood demyelination, why demyelination occurs and to better understand how demyelination affects children and adolescents.  To do this, we need to ask detailed questions about a child's early life, environment, and physical activity. To understand how demyelination affects the brain we will obtain special pictures of the brain, called magnetic resonance images (MRI). We will carefully assess all children and adolescents, not only at the time of demyelination, but also once yearly for 2 additional years.

In childhood MS, we wish to learn about quality of life, diet, and physical activity. MRI pictures of the brain and analysis of blood samples will help us also to better understand disease activity. IRB 15-012130

Metabolic MRI: Pilot Testing

The purpose of this research study is to test and adapt new techniques for performing magnetic resonance imaging (MRI). MRI provides pictures of the inside of the body and information about chemicals the body makes. Here are some examples of what we hope to accomplish:

  1. Adapt MRI techniques used at other institutions for use on CHOP MRI scanners
  2. Increase the amount of information learned from each MRI image

The research sequences involve changing the settings of the magnetic resonance scanner. By research sequences we mean that they are not approved by the US Food and Drug Administration (FDA) for clinical use. The data we obtain will help the FDA evaluate whether or not they can eventually approve the sequences for clinical use.

We are seeking to enroll healthy volunteers, 18 years of age and above. Pregnant females excluded for safety purposes. IRB 15-012204

Inhaled Insulin Afrezza® in Pediatric Patients with Type 1 Diabetes

The purpose of this research study is to test an investigational drug Afrezza® (inhaled insulin) in children and adolescents with T1DM between 4 and 17 years of age. Afrezza® is a rapid acting inhaled insulin, which was approved by Food and Drug Administration (FDA) for the treatment of diabetes in adults. Multiple doses of inhaled insulin will be evaluated over an approximate 4-week period.

Who can participate? Males or females between 4 and 17 years old in good general health, diagnosed with Type 1 Diabetes Mellitus and using insulin daily for at least 1 year

Study procedures you can expect during the study:

  • Interviews about your health
  • Physical examination
  • Blood and urine samples collection for testing
  • Lung function test
  • Electrocardiogram
  • Afrezza® administration
  • Subject Diary

If interested: Please email diabetesresearch@email.chop.edu or call 267-426-3909. IRB 15-012292


Pages